Of note, both lesions disclosed the presence of cells with the amplification of KIT, PDGFRA, VEGFR2/4q12 genes in reference to chromosome 4 centromeric probe, albeit significantly lower in number in primary versus metastatic lesion (33% vs. 81%, respectively) (Figure 4A and 4B), which was in good concordance with the tumor percentage of the biopsies by low-read-depth whole genome sequencing (17% vs. 48%, respectively). This evidence concerns the gene KIT and neoplasm.